Dietary intake of heme iron and risk of cardiovascular disease: a dose-response meta-analysis of prospective cohort studies

BACKGROUND AND AIMS

Iron is thought to play a fundamentally important role in the development of cardiovascular disease (CVD). This meta-analysis was performed to investigate the dose-response association between dietary intake of iron (including heme and non-heme iron) and the risk of CVD.

METHODS AND RESULTS

We performed a search of the PubMed and Embase databases for prospective cohort studies of the association between dietary iron intake and CVD risk. Thirteen articles comprising 252,164 participants and 15,040 CVD cases were eligible for inclusion. Heme iron intake was associated significantly with increased risk of cardiovascular disease, and the pooled relative risk (RR) for each 1 mg/day increment was 1.07 (95% confidence interval: 1.01 to 1.14, I² = 59.7%). We also found evidence of a curvilinear association (P < 0.05 for non-linearity). In contrast, we found no association between CVD risk and dietary non-heme (0.98, 0.96 to 1.01, I² = 15.8%) or total iron (1.00, 0.94 to 1.06, I² = 30.4%). Subgroup analyses revealed that the association between heme iron intake and CVD risk was stronger among non-fatal cases (1.19, 1.07-1.33) and American patients (1.31, 1.11-1.56).

CONCLUSIONS

Higher dietary intake of heme iron is associated with an increased risk of cardiovascular disease, whereas no association was found between CVD and non-heme iron intake or total iron intake. These findings may have important public health implications with respect to preventing cardiovascular disease.

The endoplasmic reticulum stress response is associated with insulin resistance-mediated drug resistance in HepG2 cells

Insulin resistance has a close relationship with tumorigenesis, tumor progression, and cancer prognosis. Importantly, the liver is the main target tissue of insulin, and the resistance to chemotherapeutic agents has been reported in hepatocarcinoma. However, little is known about the relationship between drug resistance and insulin resistance in hepatocarcinoma. Therefore, we treated HepG2 cells (a human hepatoma cell line) with high concentrations of insulin to establish a cell-based model of insulin resistance (HepG2/IR cells) to define the relationship between insulin resistance and the resistance to chemotherapy. We identified that HepG2/IR cells exhibited stable insulin resistance, with decreased glucose consumption, reduced glycogen synthesis, and decreased expression of the insulin receptor gene. HepG2/IR cells also exhibited endoplasmic reticulum (ER) dilatation and degranulation. Molecular markers of endoplasmic reticulum stress, including glucose-regulated protein78 (GRP78) and phosphorylated protein kinase R-like ER kinase (p-PERK), increased significantly, which was accompanied by increased reactive oxygen metabolism and decreased mitochondrial membrane potential. In addition, HepG2/IR cells were resistant to the chemotherapy agent Adriamycin, which was accompanied by the upregulation of multidrug resistance gene 1/ P-glycoprotein (P-gp; an endoplasmic reticulum chaperone that plays a role in ER stress), and enhanced drug efflux. These data suggest that the endoplasmic reticulum (ER) stress response was active in HepG2/IR cells, and that insulin resistance was related to drug resistance in HepG2 cells. Interestingly, the ER stress and chemotherapy resistance observed in HepG2/IR cells could be reversed by treatment with the insulin sensitizer pioglitazone. Therefore, our study suggests that there is a close relationship between the resistance to chemotherapy and insulin resistance in HepG2 cells, and that the ER stress response play a role in insulin resistance-mediated drug resistance in hepatocarcinoma cells.

KEYWORDS

Insulin resistance, drug resistance, P-gp, endoplasmic reticulum stress, HepG2 cells.

Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies

AIM

To investigate the real-world incidence of acute pancreatitis (AP) associated with incretin-based therapy (IBT).

METHODS

We carried out a systematic review and meta-analysis of observational studies using Medline, PubMed, Embase, the Cochrane Database, ClinicalTrials.gov and conference proceedings. We included: those studies in which AP was a pre-defined clinical outcome; longitudinal studies (case-control, cohort); studies that adjusted for confounders; studies that reported on a population exposed to IBT; studies in which non-IBT users or past users (who received IBTs >90 days before the index date) were used as the control group; studies that reported risk estimates [relative risks, odds ratios (ORs) or hazard ratios] with 95% confidence intervals (CIs) for AP event with IBT use, or that reported sufficient data to estimate these; and publications in the English language. Data were extracted by two independent investigators, and a consensus was reached with involvement of a third. Study-specific ORs from seven cohort studies and two case-control studies were meta-analysed using random-effects models. Associations were tested in subgroups representing different patient characteristics and study quality.

RESULTS

A total of nine studies that included 1,324,515 patients and 5195 cases of AP were included in our meta-analysis. The summary estimate of OR for an association between IBT and AP was 1.03 (95% CI 0.87-1.20).

CONCLUSIONS

The present meta-analysis of real-world data does not suggest that IBT is associated with AP. Although we should continue to remain vigilant, IBTs should be regarded as reasonable options to consider adding to the regimen of a patient with type 2 diabetes.

Treatment of different-aged children under bispectral index monitoring with intravenous anesthesia with propofol and remifentanil

OBJECTIVE

To investigate the changes in bispectral index (BIS) to determine the controllability and safety of intravenous anesthesia with propofol and remifentanil in different-aged children.

PATIENTS AND METHODS

Forty cases of ASA levels I or II were divided into four groups (A group, ≤ three months old; B group, three months to two years old; C group, two years to six years old; and D group, six years to 12 years old) with 10 cases in each group. Propofol and remifentanil were used in anesthesia induction and maintenance. Hemodynamic changes, BIS values, and sedation scores during T1, T2, T3, T4, T5, T6, and T7, as well as spontaneous breathing recovery and extubation times, were recorded.

RESULTS

Compared with that at T1, the BIS values at T2, T3, T4, T5, and T6 decreased (p < 0.01). SBP, DBP, and HR also decreased (p < 0.01). Compared with the other groups, the extubation time of A group increased (p < 0.01). At T2, T3, T4, T5, T6, and T7, the BIS values of A group were all less than those of C group (p < 0.01).

CONCLUSIONS

Anesthesia is stable and safe when the same unit doses of propofol and remifentanil are administered to different-aged children. In infants under three months, the BIS values were lower, with prolonged palinesthesia time.

Measurement of prompt ψ(2S) to J/ψ yield ratios in Pb-Pb and p-p collisions at sqrt[sNN]=2.76 TeV

The ratio between the prompt ψ(2S) and J/ψ yields, reconstructed via their decays into μ+ μ-, is measured in Pb-Pb and p-p collisions at sqrt[sNN]=2.76  TeV. The analysis is based on Pb-Pb and p-p data samples collected by CMS at the Large Hadron Collider, corresponding to integrated luminosities of 150  μb(-1) and 5.4  pb(-1), respectively. The double ratio of measured yields (Nψ(2S)/N(J/ψ))(Pb-Pb)/(Nψ(2S)/N(J/ψ))(p-p) is computed in three Pb-Pb collision centrality bins and two kinematic ranges: one at midrapidity, |y|<1.6, covering the transverse momentum range 6.5<pT<30  GeV/c, and the other at forward rapidity, 1.6<|y|<2.4, extending to lower pT values, 3<pT<30  GeV/c. The centrality-integrated double ratio changes from 0.45±0.13(stat)±0.07(syst) in the first range to 1.67±0.34(stat)±0.27(syst) in the second. This difference is most pronounced in the most central collisions.

4q27 as a psoriasis susceptibility locus in the Northeastern Chinese Han population

Psoriasis is an autoimmune inflammatory skin disease with genetic components. Chromosome 4q27 is related to many autoimmune diseases, however, the relationship between psoriasis and 4q27 has not been fully established yet. The objective of this study is to investigate the association between chromosome 4q27 and psoriasis in the Northeastern Chinese Han population. Four common single nucleotide polymorphisms (rs2069762, rs4833837, rs6840978, and rs7684187) from chromosome 4q27 were genotyped in 400 psoriasis cases and 398 controls from the Northeastern Chinese Han population using the Multiplex SNaPSHOT method. Single nucleotide polymorphism and haplotype frequencies were analyzed using spss 13.0. Our data indicated that rs2069762 GG, TG genotypes [GG: odds ratio (OR) = 2.6875, 95% confidence interval (CI) = 1.5948-4.5290, P < 0.0001; TG: OR = 1.6159, 95% CI = 1.2044-2.1681, P = 0.0013], and H3 haplotype (OR = 1.717, 95% CI = 1.050-2.808, P = 0.030) increased the risk of psoriasis. Furthermore, rs4833837 GG, GA genotypes (GG: OR = 0.2071, 95% CI = 0.0685-0.6266, P = 0.0022; GA: OR = 0.4711, 95% CI = 0.3289-0.6746, P < 0.0001), and H5 haplotype (OR = 0.482, 95% CI = 0.238-0.978, P = 0.039) were identified as protective factors for psoriasis. 4q27 polymorphisms are associated with psoriasis in the Northeastern Chinese Han population.

Denis RD, Staerz S, Stahlman J, Stamen R, Stamm S, Stanecka E, Stanek RW, Stanescu C, Stanescu-Bellu M, Stanitzki MM, Stapnes S, Starchenko EA, Stark J, Staroba P, Starovoitov P, Staszewski R, Stavina P, Steinberg P, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stern S, Stewart GA, Stillings JA, Stockton MC, Stoebe M, Stoicea G, Stolte P, Stonjek S, Stradling AR, Straessner A, Stramaglia ME, Strandberg J, Strandberg S, Strandlie A, Strauss E, Strauss M, Strizenec P, Ströhmer R, Strom DM, Stroynowski R, Stucci SA, Stugu B, Styles NA, Su D, Su J, Subramaniam R, Succurro A, Sugaya Y, Suhr C, Suk M, Sulin VV, Sultansoy S, Sumida T, Sun S, Sun X, Sundermann JE, Suruliz K, Susinno G, Sutton MR, Suzuki Y, Svatos M, Swedish S, Swiatlowski M, Sykora I, Sykora T, Ta D, Taccini C, Tackmann K, Taenzer J, Taffard A, Tafirout R, Taiblum N, Takai H, Takashima R, Takeda H, Takeshita T, Takubo Y, Talby M, Talyshev AA, Tam JYC, Tan KG, Tanaka J, Tanaka R, Tanaka S, Tanaka S, Tanasijczuk AJ, Tannenwald BB, Tannoury N, Tapprogge S, Tarem S, Tarrade F, Tartarelli GF, Tas P, Tasevsky M, Tashiro T, Tassi E, Tavares Delgado A, Tayalati Y, Taylor FE, Taylor GN, Taylor W, Teischinger FA, Teixeira Dias Castanheira M, Teixeira-Dias P, Temming KK, Ten Kate H, Teng PK, Teoh JJ, Terada S, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Therhaag J, Theveneaux-Pelzer T, Thomas JP, Thomas-Wilsker J, Thompson EN, Thompson PD, Thompson PD, Thompson RJ, Thompson AS, Thomsen LA, Thomson E, Thomson M, Thong WM, Thun RP, Tian F, Tibbetts MJ, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tiouchichine E, Tipton P, Tisserant S, Todorov T, Todorova-Nova S, Toggerson B, Tojo J, Tokár S, Tokushuku K, Tollefson K, Tomlinson L, Tomoto M, Tompkins L, Toms K, Topilin ND, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Tran HL, Trefzger T, Tremblet L, Tricoli A, Trigger IM, Trincaz-Duvoid S, Tripiana MF, Trischuk W, Trocmé B, Troncon C, Trottier-McDonald M, Trovatelli M, True P, Trzebinski M, Trzupek A, Tsarouchas C, Tseng JCL, Tsiareshka PV, Tsionou D, Tsipolitis G, Tsirintanis N, Tsiskaridze S, Tsiskaridze V, Tskhadadze EG, Tsukerman II, Tsulaia V, Tsuno S, Tsybychev D, Tudorache A, Tudorache V, Tuna AN, Tupputi SA, Turchikhin S, Turecek D, Turk Cakir I, Turra R, Tuts PM, Tykhonov A, Tylmad M, Tyndel M, Uchida K, Ueda I, Ueno R, Ughetto M, Ugland M, Uhlenbrock M, Ukegawa F, Unal G, Undrus A, Unel G, Ungaro FC, Unno Y, Unverdorben C, Urbaniec D, Urquijo P, Usai G, Usanova A, Vacavant L, Vacek V, Vachon B, Valencic N, Valentinetti S, Valero A, Valery L, Valkar S, Valladolid Gallego E, Vallecorsa S, Valls Ferrer JA, Van Den Wollenberg W, Van Der Deijl PC, van der Geer R, van der Graaf H, Van Der Leeuw R, van der Ster D, van Eldik N, van Gemmeren P, Van Nieuwkoop J, van Vulpen I, van Woerden MC, Vanadia M, Vandelli W, Vanguri R, Vaniachine A, Vankov P, Vannucci F, Vardanyan G, Vari R, Varnes EW, Varol T, Varouchas D, Vartapetian A, Varvell KE, Vazeille F, Vazquez Schroeder T, Veatch J, Veloso F, Veneziano S, Ventura A, Ventura D, Venturi M, Venturi N, Venturini A, Vercesi V, Verducci M, Verkerke W, Vermeulen JC, Vest A, Vetterli MC, Viazlo O, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Vigne R, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinogradov VB, Virzi J, Vivarelli I, Vives Vaque F, Vlachos S, Vladoiu D, Vlasak M, Vogel A, Vogel M, Vokac P, Volpi G, Volpi M, von der Schmitt H, von Radziewski H, von Toerne E, Vorobel V, Vorobev K, Vos M, Voss R, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vu Anh T, Vuillermet R, Vukotic I, Vykydal Z, Wagner P, Wagner W, Wahlberg H, Wahrmund S, Wakabayashi J, Walder J, Walker R, Walkowiak W, Wall R, Waller P, Walsh B, Wang C, Wang C, Wang F, Wang H, Wang H, Wang J, Wang J, Wang K, Wang R, Wang SM, Wang T, Wang X, Wanotayaroj C, Warburton A, Ward CP, Wardrope DR, Warsinsky M, Washbrook A, Wasicki C, Watkins PM, Watson AT, Watson IJ, Watson MF, Watts G, Watts S, Waugh BM, Webb S, Weber MS, Weber SW, Webster JS, Weidberg AR, Weigell P, Weinert B, Weingarten J, Weiser C, Weits H, Wells PS, Wenaus T, Wendland D, Weng Z, Wengler T, Wenig S, Wermes N, Werner M, Werner P, Wessels M, Wetter J, Whalen K, White A, White MJ, White R, White S, Whiteson D, Wicke D, Wickens FJ, Wiedenmann W, Wielers M, Wienemann P, Wiglesworth C, Wiik-Fuchs LAM, Wijeratne PA, Wildauer A, Wildt MA, Wilkens HG, Will JZ, Williams HH, Williams S, Willis C, Willocq S, Wilson A, Wilson JA, Wingerter-Seez I, Winklmeier F, Winter BT, Wittgen M, Wittig T, Wittkowski J, Wollstadt SJ, Wolter MW, Wolters H, Wosiek BK, Wotschack J, Woudstra MJ, Wozniak KW, Wright M, Wu M, Wu SL, Wu X, Wu Y, Wulf E, Wyatt TR, Wynne BM, Xella S, Xiao M, Xu D, Xu L, Yabsley B, Yacoob S, Yakabe R, Yamada M, Yamaguchi H, Yamaguchi Y, Yamamoto A, Yamamoto K, Yamamoto S, Yamamura T, Yamanaka T, Yamauchi K, Yamazaki Y, Yan Z, Yang H, Yang H, Yang UK, Yang Y, Yanush S, Yao L, Yao WM, Yasu Y, Yatsenko E, Yau Wong KH, Ye J, Ye S, Yeletskikh I, Yen AL, Yildirim E, Yilmaz M, Yoosoofmiya R, Yorita K, Yoshida R, Yoshihara K, Young C, Young CJS, Youssef S, Yu DR, Yu J, Yu JM, Yu J, Yuan L, Yurkewicz A, Yusuff I, Zabinski B, Zaidan R, Zaitsev AM, Zaman A, Zambito S, Zanello L, Zanzi D, Zeitnitz C, Zeman M, Zemla A, Zengel K, Zenin O, Ženiš T, Zerwas D, Zevi della Porta G, Zhang D, Zhang F, Zhang H, Zhang J, Zhang L, Zhang X, Zhang Z, Zhao Z, Zhemchugov A, Zhong J, Zhou B, Zhou L, Zhou N, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zibell A, Zieminska D, Zimine NI, Zimmermann C, Zimmermann R, Zimmermann S, Zimmermann S, Zinonos Z, Ziolkowski M, Zobernig G, Zoccoli A, zur Nedden M, Zurzolo G, Zutshi V, Zwalinski L. Search for contact interactions and large extra dimensions in the dilepton channel using proton-proton collisions at [Formula: see text] 8 TeV with the ATLAS detector

A search is conducted for non-resonant new phenomena in dielectron and dimuon final states, originating from either contact interactions or large extra spatial dimensions. The LHC 2012 proton-proton collision dataset recorded by the ATLAS detector is used, corresponding to 20 fb[Formula: see text] at [Formula: see text] = 8 TeV. The dilepton invariant mass spectrum is a discriminating variable in both searches, with the contact interaction search additionally utilizing the dilepton forward-backward asymmetry. No significant deviations from the Standard Model expectation are observed. Lower limits are set on the [Formula: see text] contact interaction scale [Formula: see text] between 15.4 TeV and 26.3 TeV, at the 95 % credibility level. For large extra spatial dimensions, lower limits are set on the string scale [Formula: see text] between 3.2 TeV to 5.0 TeV.

Measurement of distributions sensitive to the underlying event in inclusive Z-boson production in [Formula: see text] collisions at [Formula: see text] TeV with the ATLAS detector

A measurement of charged-particle distributions sensitive to the properties of the underlying event is presented for an inclusive sample of events containing a [Formula: see text]-boson, decaying to an electron or muon pair. The measurement is based on data collected using the ATLAS detector at the LHC in proton-proton collisions at a centre-of-mass energy of [Formula: see text] TeV with an integrated luminosity of [Formula: see text] fb[Formula: see text]. Distributions of the charged particle multiplicity and of the charged particle transverse momentum are measured in regions of azimuthal angle defined with respect to the [Formula: see text]-boson direction. The measured distributions are compared to similar distributions measured in jet events, and to the predictions of various Monte Carlo generators implementing different underlying event models.

A measurement of the ratio of the production cross sections for [Formula: see text] and [Formula: see text] bosons in association with jets with the ATLAS detector

The ratio of the production cross sections for [Formula: see text] and [Formula: see text] bosons in association with jets has been measured in proton-proton collisions at [Formula: see text] with the ATLAS experiment at the Large Hadron Collider. The measurement is based on the entire 2011 dataset, corresponding to an integrated luminosity of [Formula: see text]. Inclusive and differential cross-section ratios for massive vector bosons decaying to electrons and muons are measured in association with jets with transverse momentum [Formula: see text] and jet rapidity [Formula: see text]. The measurements are compared to next-to-leading-order perturbative QCD calculations and to predictions from different Monte Carlo generators implementing leading-order matrix elements supplemented by parton showers.

Screening of highly informative and representative microsatellite markers for genotyping of major cultivated cotton varieties

We screened and assessed published cotton simple sequence repeat (SSR) primers to establish a set of core SSR markers suitable for cotton major cultivars in China and analyzed genetic diversity based on the core marker set. Using a stepwise screening strategy, 12 leading cultivars for preliminary screening and 96 cultivars for rescreening were evaluated. A total of 184 polymorphic SSR markers were initially screened from 3299 candidates, and a core set of 52 SSR markers with wide genome coverage (2 markers per chromosome) was obtained. Among 96 major cultivars, 273 amplification genotypes were generated using the core marker set. Polymorphism information content values ranged from 0.28-0.83, with an average value of 0.56. The core SSR marker set detected on denaturing polyacrylamide gel electrophoresis indicated that the band genotype was either a single or double band on conventional cultivars, while most were double bands (65.4%). Among 56 hybrids, the average heterozygosis rate was 35.8%, ranging from 7.1-55.4%. Eighteen of 96 cultivars had distinct band genotypes. The genetic diversity analyzed using the of NTSYS-pc V2.10 software indicated that the Yangtze River valley cotton region had the highest polymorphic level, followed by Xinjiang and then the Yellow River valley. The genetic basis of conventional cultivars was narrower than that of hybrids. The core marker set can be used for fingerprint construction, variety identification, and purity tests of major cotton cultivars in China.